{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:49:38Z","timestamp":1780606178829,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10072-016-2769-5","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T08:57:33Z","timestamp":1479718653000},"page":"325-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis"],"prefix":"10.1007","volume":"38","author":[{"given":"Xiaoyong","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongning","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xusheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"2769_CR1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1756285615571873","volume":"8","author":"JL Cruz","year":"2015","unstructured":"Cruz JL, Wolff ML, Vanderman AJ, Brown JN (2015) The emerging role of tacrolimus in Myasthenia Gravis. Ther Adv Neurol Disord 8:92\u2013103","journal-title":"Ther Adv Neurol Disord"},{"key":"2769_CR2","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487\u20131489","journal-title":"Neurology"},{"key":"2769_CR3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","volume":"300","author":"N Minami","year":"2011","unstructured":"Minami N, Fujiki N, Doi S (2011) Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci 300:59\u201362","journal-title":"J Neurol Sci"},{"issue":"6","key":"2769_CR4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","volume":"17","author":"AW Thomson","year":"1995","unstructured":"Thomson AW, Bonham CA, Zeevi A (1995) Dec mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 17(6):584\u2013591 (review)","journal-title":"Ther Drug Monit"},{"key":"2769_CR5","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/mus.21055","volume":"38","author":"GD Meekins","year":"2008","unstructured":"Meekins GD, So Y, Quan D (2008) American association of neuromuscular & electrodiagnostic medicine evidenced-based review: use of surface electromyography in the diagnosis and study of neuromuscular disorders. Muscle Nerve 38:1219\u20131224","journal-title":"Muscle Nerve"},{"key":"2769_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of america. Ann Thorac Surg 70:327\u2013334","journal-title":"Ann Thorac Surg"},{"key":"2769_CR7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.10018","volume":"25","author":"A Evoli","year":"2002","unstructured":"Evoli A, Di Schino C, Marsili F, Punzi C (2002) Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 25:111\u2013114","journal-title":"Muscle Nerve"},{"key":"2769_CR8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.10472","volume":"28","author":"T Konishi","year":"2003","unstructured":"Konishi T, Yoshiyama Y, Takamori M (2003) Clinical study of fk506 in patients with myasthenia gravis. Muscle Nerve 28:570\u2013574","journal-title":"Muscle Nerve"},{"key":"2769_CR9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","volume":"11","author":"CB Zhao","year":"2011","unstructured":"Zhao CB, Zhang X, Zhang H (2011) Clinical efficacy and immunological impact of tacrolimus in chinese patients with generalized myasthenia gravis. Int Immunopharmacol 11:519\u2013524","journal-title":"Int Immunopharmacol"},{"key":"2769_CR10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","volume":"53","author":"Y Nagane","year":"2005","unstructured":"Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y (2005) Efficacy of low-dose fk506 in the treatment of myasthenia gravis\u2013a randomized pilot study. Eur Neurol 53:146\u2013150","journal-title":"Eur Neurol"},{"key":"2769_CR11","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","volume":"64","author":"JM Ponseti","year":"2005","unstructured":"Ponseti JM, Azem J, Fort JM (2005) Long-term results of tacrolimus in cyclosporine-and prednisone-dependent myasthenia gravis. Neurology 64:1641\u20131643","journal-title":"Neurology"},{"key":"2769_CR12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","volume":"1132","author":"JM Ponseti","year":"2008","unstructured":"Ponseti JM, Gamez J, Azem J, Lopez-Cano M, Vilallonga R, Armengol M (2008) Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci 1132:254\u2013263","journal-title":"Ann N Y Acad Sci"},{"key":"2769_CR13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/11587050-000000000-00000","volume":"50","author":"F Glowacki","year":"2011","unstructured":"Glowacki F, Lionet A, Hammelin JP (2011) Influence of cytochrome p450 3a5 (cyp3a5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet 50:451\u2013459","journal-title":"Clin Pharmacokinet"},{"key":"2769_CR14","doi-asserted-by":"crossref","unstructured":"Op den Buijsch RA, Christiaans MH, Stolk LM et al (2007) Tacrolimus pharmacokinetics: influence of adenosine triphosphate-binding cassette b1 (abcb1) and cytochrome (cyp) 3a polymorphisms. Fundam Clin Pharmacol 21:427\u2013435","DOI":"10.1111\/j.1472-8206.2007.00504.x"},{"key":"2769_CR15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1399-3046.2006.00662.x","volume":"11","author":"M Ferraresso","year":"2007","unstructured":"Ferraresso M, Tirelli A, Ghio L et al (2007) Influence of the cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 11:296\u2013300","journal-title":"Pediatr Transplant"},{"key":"2769_CR16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/phgs.5.3.243.29833","volume":"5","author":"HG Xie","year":"2004","unstructured":"Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR (2004) Genetic variability in cyp3a5 and its possible consequences. Pharmacogenomics 5:243\u2013272","journal-title":"Pharmacogenomics"},{"key":"2769_CR17","doi-asserted-by":"crossref","unstructured":"Tada M, Shimohata T, Tada M, et al (2006) Long-term therapeutic efficacy and safety of low-dose tacrolimus (fk506) for Myasthenia Gravis. J Neurol Sci 247:17\u201320","DOI":"10.1016\/j.jns.2006.03.010"},{"key":"2769_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2006.03.010","volume":"247","author":"M Tada","year":"2006","unstructured":"Tada M, Shimohata T, Tada M, et al (2006) Long-term therapeutic efficacy and safety of low-dose tacrolimus (fk506) for Myasthenia Gravis. J Neurol Sci 247:17\u201320.","journal-title":"J Neurol Sci"},{"key":"2769_CR19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2007.12.008","volume":"195","author":"Y Furukawa","year":"2008","unstructured":"Furukawa Y, Yoshikawa H, Iwasa K, Yamada M (2008) Clinical efficacy and cytokine network-modulating effects of tacrolimus in Myasthenia Gravis. J Neuroimmunol 195:108\u2013115","journal-title":"J Neuroimmunol"},{"key":"2769_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","volume":"53","author":"DB Drachman","year":"2003","unstructured":"Drachman DB, Jones RJ, Brodsky RA (2003) Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide. Ann Neurol 53:29\u201334","journal-title":"Ann Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-016-2769-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-016-2769-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-016-2769-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T20:13:16Z","timestamp":1568578396000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-016-2769-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2769"],"URL":"https:\/\/doi.org\/10.1007\/s10072-016-2769-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}